Companies › Astellas
28 active drug programs in 134 registered trials: 56 Phase 2, 43 Phase 1, 23 Phase 3, 12 Phase 4; Oncology, Neurology, Ophthalmology, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Enfortumab Vedotin Nectin-4 binding agent; Tubulin inhibitor | NECTIN4, Tubulin | Phase 4 | Metastatic Urothelial Carcinoma; Urothelial Cancer; Locally Advanced or Metastatic Malignant Solid Tumors; Muscle-invasive Bladder Cancer … | Dec 2026 |
| Avacincaptad Pegol Sodium (ASP3021) Complement C5 inhibitor | C5 | Phase 4 | Geographic Atrophy | Jun 2027 |
| zolbetuximab Claudin-18 binding agent | CLDN18 | Phase 3 | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Pancreatic Cancer; Pharmacokinetics of Zolbetuximab; Metastatic Pancreatic Adenocarcinoma … | Dec 2026 |
| fezolinetant Neurokinin 3 receptor antagonist | TACR3 | Phase 3 | Hot Flashes; Prostate Cancer; Prostate CA; Vasomotor Symptoms … | Apr 2027 |
| Setidegrasib (ASP3082) KRAS G12D inhibitor | KRAS | Phase 3 | Pancreatic Cancer; Non-small Cell Lung Cancer (NSCLC); Healthy Volunteer | May 2027 |
| Roxadustat Hypoxia-inducible factor prolyl hydroxylase inhibitor | EGLN2, P4HTM, EGLN1, EGLN3 | Phase 3 | Chronic Kidney Disease; Dialysis; Complications; Perioperative Anemia; Kidney Failure, Chronic … | Oct 2027 |
| ASP2138 Bispecific antibody binding CLDN18.2 on tumor cells and CD3E on T cells | CD3E, CLDN18 | Phase 3 | Gastric Adenocarcinoma; Pancreatic Ductal Adenocarcinoma | Jan 2028 |
| Fezolinetant Neurokinin 3 receptor antagonist | TACR3 | Phase 3 | Hot Flashes | Mar 2028 |
| Enzalutamide Androgen Receptor antagonist | AR | Phase 3 | Metastatic Hormone Sensitive Prostate Cancer | Dec 2028 |
| mirabegron Beta-3 adrenergic receptor agonist | ADRB3 | Phase 3 | Neurogenic Detrusor Overactivity; Overactive Bladder Syndrome; Effect of Drug; Urinary Bladder, Overactive … | – |
| ASP5541 CYP17A1 inhibitor (17α-hydroxylase/17,20-lyase inhibitor); intramuscular depot formulation | CYP17A1 | Phase 2 | Prostate Cancer | Oct 2028 |
| enzalutamide Androgen Receptor antagonist | AR | Phase 2 | Prostate Cancer | Jul 2029 |
| Resamirigene bilparvovec (AT132) AAV8 vector containing a functional copy of the human MTM1 gene | MTM1 | Phase 2 | X-Linked Myotubular Myopathy | Mar 2030 |
| ASP546C (XNW27011) anti-CLDN18.2 antibody-drug conjugate | CLDN18 | Phase 1 | Pancreatic Adenocarcinoma Metastatic; Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma | Dec 2026 |
| ASP2390 House dust mite immunotherapy | – | Phase 1 | Allergic to House Dust Mites | Dec 2026 |
| VIR-5500 (AMX-500) | – | Phase 1 | Hormone-refractory Prostate Cancer | Sep 2027 |
| ASP2957 AAV gene therapy delivering MTM1 gene with MHCK7 promoter and MyoAAV3.8 engineered capsid | MTM1 | Phase 1 | X-Linked Myotubular Myopathy | Oct 2027 |
| ASP7317 Retinal pigment epithelium (RPE) cells derived from human pluripotent stem cells | – | Phase 1 | Age-Related Macular Degeneration | Dec 2027 |
| Gilteritinib Tyrosine-protein kinase receptor FLT3 inhibitor; Tyrosine-protein kinase receptor UFO inhibitor | FLT3, AXL | Phase 1 | Acute Myeloid Leukemia (AML); Non-small Cell Lung Cancer (NSCLC); AML (Acute Myeloid Leukemia); Acute Myeloid Leukemia … | Jul 2028 |
| ASP5834 KRAS mutant inhibitor | KRAS | Phase 1 | Solid Tumor | Nov 2028 |
| PRL-02 injection Abiraterone decanoate - CYP17A1 inhibitor for testosterone reduction | CYP17A1 | Phase 1 | Prostate Cancer | May 2029 |
| ASP2998 anti-TROP2 antibody-drug conjugate | TROP2 | Phase 1 | Locally Advanced or Metastatic Malignant Solid Tumors | Jun 2029 |
| ASP2020 Gene therapy for macular dystrophy | – | Phase 1 | Stargardt Disease | Sep 2029 |
| ASP2246 | – | Phase 1 | Chronic Ischemic Stroke | Feb 2030 |
| ASP388B | – | Phase 1 | Locally Advanced or Metastatic Solid Tumors | Feb 2030 |
| ASP1002 Anti-CLDN4 antibody-drug conjugate | CLDN4 | Phase 1 | Advanced Solid Tumors | Apr 2030 |
| ASP2767 Gene therapy using harmless viral vector to deliver genes that promote neuroprotective pro | – | Phase 1 | Glaucoma | Jul 2030 |
| zocaglusagene nuzaparvovec (AT845) AAV8 vector delivering functional human GAA gene under muscle-specific promoter | GAA | Phase 1 | Pompe Disease (Late-onset) | Feb 2035 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05915351 | Enfortumab Vedotin | Phase 2 | Pancreatic Ductal Adenocarcinoma | Oncology | Jun 2025 |
| NCT06903559 | Roxadustat | Phase 1 | Kidney Failure, Chronic | Genitourinary | Oct 2025 |
| NCT06917950 | Roxadustat | Phase 1 | Kidney Failure,Chronic | Psychiatry | Oct 2025 |
| NCT07199894 | mirabegron | Phase 3 | Nocturnal Enuresis in Children | Psychiatry | Dec 2025 |
| NCT05621616 | mirabegron | Phase 3 | Neurogenic Detrusor Overactivity | Genitourinary | Feb 2026 |
| NCT07773129 | Setidegrasib (ASP3082) | Phase 1 | Healthy Volunteer | Other | Oct 2026 |
| NCT03816163 | zolbetuximab | Phase 2 | Pancreatic Cancer | Oncology | Oct 2026 |
| NCT07398261 | mirabegron | Phase 3 | Treatment of Non-monosymptomatic Nocturnal Enuresis | Psychiatry | Nov 2026 |
| NCT06772272 | Roxadustat | Phase 3 | Perioperative Anemia | Hematology | Nov 2026 |
| NCT04963153 | Enfortumab Vedotin | Phase 1 | Locally Advanced Bladder Urothelial Carcinoma | Oncology | Dec 2026 |
| NCT07712848 | Gilteritinib | Phase 3 | AML (Acute Myeloid Leukemia) | Oncology | Dec 2026 |
| NCT05756569 | Enfortumab Vedotin | Phase 2 | Bladder Squamous Cell Carcinoma | Oncology | Dec 2026 |
| NCT06792435 | ASP546C (XNW27011) | Phase 1 | Pancreatic Adenocarcinoma Metastatic | Oncology | Dec 2026 |
| NCT05221021 | mirabegron | Phase 4 | Overactive Bladder Syndrome | Genitourinary | Dec 2026 |
| NCT06396091 | zolbetuximab | Phase 1 | Metastatic Pancreatic Adenocarcinoma | Oncology | Dec 2026 |
| NCT06862219 | Enfortumab Vedotin | Phase 4 | Metastatic Urothelial Carcinoma | Oncology | Dec 2026 |
| NCT05010772 | Gilteritinib | Phase 1 | Acute Myeloid Leukemia | Oncology | Dec 2026 |
| NCT04184895 | ASP2390 | Phase 1 | Allergic to House Dust Mites | Immunology | Dec 2026 |
| NCT06479720 | mirabegron | Phase 4 | Effect of Drug | Genitourinary | Dec 2026 |
| NCT05968885 | mirabegron | Phase 4 | Urinary Bladder, Overactive | Genitourinary | Dec 2026 |
| NCT06803030 | mirabegron | Phase 3 | Ureteral Stent-Related Symptom | Other | Dec 2026 |
| NCT05775471 | Enfortumab Vedotin | Phase 2 | Renal Pelvis and Ureter Urothelial Carcinoma | Oncology | Jan 2027 |
| NCT06904573 | Enfortumab Vedotin | Phase 2 | Advanced Urothelial Carcinoma | Oncology | Jan 2027 |
| NCT06972875 | fezolinetant | Phase 2 | Prostate CA | Oncology | Jan 2027 |
| NCT04754191 | Enfortumab Vedotin | Phase 2 | Metastatic Castration-resistant Prostate Cancer | Oncology | Jan 2027 |
| NCT05051436 | mirabegron | Phase 4 | Pre-diabetes | Metabolic and endocrine | Jan 2027 |
| NCT06222580 | Gilteritinib | Phase 1 | Acute Myeloid Leukemia With FLT3/ITD Mutation | Oncology | Jan 2027 |
| NCT04724018 | Enfortumab Vedotin | Phase 1 | Urothelial Cancer | Oncology | Feb 2027 |
| NCT05024552 | Gilteritinib | Phase 1 | Acute Myeloid Leukemia With FLT3/ITD Mutation | Oncology | Feb 2027 |
| NCT06891560 | Enfortumab Vedotin | Phase 2 | Adenoid Cystic Carcinoma | Oncology | Mar 2027 |
| NCT03504397 | zolbetuximab | Phase 3 | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Oncology | Mar 2027 |
| NCT03653507 | zolbetuximab | Phase 3 | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Oncology | Mar 2027 |
| NCT04225117 | Enfortumab Vedotin | Phase 2 | Locally Advanced or Metastatic Malignant Solid Tumors | Oncology | Mar 2027 |
| NCT05604222 | mirabegron | Phase 4 | Urgency Urinary Incontinence | Genitourinary | Mar 2027 |
| NCT07647289 | Enfortumab Vedotin | Phase 2 | Muscle-Invasive Bladder Cancer (MIBC) | Oncology | Apr 2027 |
| NCT05756777 | Gilteritinib | Phase 1 | Acute Myeloid Leukemia (AML) | Oncology | Apr 2027 |
| NCT07783282 | fezolinetant | Phase 1 | Prostate Cancer | Oncology | Apr 2027 |
| NCT07395024 | Setidegrasib (ASP3082) | Phase 1 | Healthy Volunteer | Other | May 2027 |
| NCT06225427 | Gilteritinib | Phase 1 | Lung Non-Small Cell Carcinoma | Oncology | May 2027 |
| NCT05868265 | Enfortumab Vedotin | Phase 2 | Urothelial Carcinoma | Oncology | Jun 2027 |
| NCT05239624 | Enfortumab Vedotin | Phase 2 | Urothelial Carcinoma | Oncology | Jun 2027 |
| NCT06906822 | Enfortumab Vedotin | Phase 2 | Melanoma | Oncology | Jun 2027 |
| NCT04666636 | mirabegron | Phase 2 | PreDiabetes | Metabolic and endocrine | Jun 2027 |
| NCT03505320 | zolbetuximab | Phase 2 | Pharmacokinetics of Zolbetuximab | Oncology | Jun 2027 |
| NCT06970665 | Avacincaptad Pegol Sodium (ASP3021) | Phase 4 | Geographic Atrophy | Ophthalmology | Jun 2027 |
| NCT05369351 | mirabegron | Phase 2 | Intracerebral Haemorrhage | Neurology | Aug 2027 |
| NCT06434350 | Enfortumab Vedotin | Phase 1 | Advanced Bladder Cancer | Oncology | Sep 2027 |
| NCT05879653 | Enfortumab Vedotin | Phase 2 | Bladder Cancer | Oncology | Sep 2027 |
| NCT05997615 | VIR-5500 (AMX-500) | Phase 1 | Hormone-refractory Prostate Cancer | Oncology | Sep 2027 |
| NCT06041503 | Enfortumab Vedotin | Phase 2 | Adenocarcinoma of the Bladder | Oncology | Oct 2027 |
| NCT06235801 | Gilteritinib | Phase 1 | Myeloid Leukemia | Oncology | Oct 2027 |
| NCT06551246 | mirabegron | Phase 3 | Urinary Incontinence in Children | Genitourinary | Oct 2027 |
| NCT06302569 | Enfortumab Vedotin | Phase 2 | Bellini Carcinoma | Oncology | Oct 2027 |
| NCT06022003 | Gilteritinib | Phase 2 | AML, Adult | Oncology | Oct 2027 |
| NCT05970172 | Roxadustat | Phase 3 | Chronic Kidney Disease | Genitourinary | Oct 2027 |
| NCT07052929 | ASP2957 | Phase 1 | X-Linked Myotubular Myopathy | Neurology | Oct 2027 |
| NCT04878029 | Enfortumab Vedotin | Phase 1 | Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation | Oncology | Nov 2027 |
| NCT06809140 | Enfortumab Vedotin | Phase 2 | Muscle Invasive Bladder Urothelial Carcinoma | Oncology | Nov 2027 |
| NCT07475806 | Enfortumab Vedotin | Phase 2 | Muscle-invasive Bladder Cancer | Oncology | Nov 2027 |
| NCT07139977 | Enfortumab Vedotin | Phase 2 | Endometrial Cancer | Oncology | Nov 2027 |
The 60 nearest readouts of 134 trials; the rest in the app.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.